Frequently Asked Questions
The Diabetic lancing device market is to reach an estimated value of USD 1,742.01 million and is growing at a CAGR of 10.28% in the forecasted period by 2028.
Diabetic lancing device market is segmented on the basis of type, gauge, penetration depth and application.
The countries covered in the diabetic lancing device market report are U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America.
The major players covered in the diabetic lancing device market report are BD, F. Hoffmann-La Roche Ltd, Johnson & Johnson Services, Inc., Sanofi, Novo Nordisk A/S, Ypsomed Holding, Ascensia Diabetes Care Holdings AG, Dexcom, Inc., ARKRAY USA, Inc., Bayer AG, Amylin Pharmaceuticals Inc., Abbott, Medtronic Inc., Teva Pharmaceuticals Pvt Ltd., Home Diagnostics Inc., Novartis AG, Eli Lilly and Company, Merck & Co., Inc, AstraZeneca, Boehringer Ingelheim International GmbH. and Terumo Corporation
North America dominates the diabetic lancing device market due to rising prevalence of diabetes coupled with growing preference for diabetes lancing devices in this region.
